Literature DB >> 15240122

Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells.

Christina Löfgren1, Linn Hjortsberg, Malin Blennow, Kourosh Lotfi, Christer Paul, Staffan Eriksson, Freidoun Albertioni.   

Abstract

The aim of this study was to clarify the biochemical and molecular mechanisms behind the cross-resistance to nucleoside analogues (NAs) in four erythroleukemic cell lines with acquired resistance to the anthracycline daunorubicin and to the vinca alkaloid vincristine, expressing high levels of p-glycoprotein (P-gp, MDR1). All resistant strains exhibited cross-resistance to NA (cladribine and cytosine arabinoside)-induced apoptosis, assessed by caspase-3-like activation and were less sensitive to NA cytotoxicity in MTT assay. Real-time PCR and enzyme activity analysis showed reduced amounts of deoxycytidine kinase (35-80%) and elevated levels of 5'-nucleotidases (50-100%). The ratio 5'-nucleotidase to deoxycytidine kinase increased between 2.5- and 7.5-folds in resistant cells. This is in agreement with the observation that 5'-nucleotidase/deoxycytidine kinase ratio might be an important factor in predicting resistance to NAs. Implications of this finding for combining anthracyclines or vinca alkaloids with NAs toward leukemic cells are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240122     DOI: 10.1016/j.bbrc.2004.06.016

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Immune Repertoire and Advancements in Nanotherapeutics for the Impediment of Severe Steroid Resistant Asthma (SSR).

Authors:  Narasimha M Beeraka; Runze Zhou; Xiaoyan Wang; Hemanth Vikram P R; Tegginamath Pramod Kumar; Junqi Liu; M V Greeshma; Subhankar P Mandal; B M Gurupadayya; Ruitai Fan
Journal:  Int J Nanomedicine       Date:  2022-05-12

2.  Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.

Authors:  A H Beesley; M-L Palmer; J Ford; R E Weller; A J Cummings; J R Freitas; M J Firth; K U Perera; N H de Klerk; U R Kees
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

3.  CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance.

Authors:  Anette Langebäck; Smaranda Bacanu; Henriette Laursen; Lisanne Mout; Takahiro Seki; Sigrun Erkens-Schulze; Anderson Daniel Ramos; Anna Berggren; Yihai Cao; Johan Hartman; Wytske van Weerden; Jonas Bergh; Pär Nordlund; Sara Lööf
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.